Immunizing small cell lung cancer mice with isoaspartylated Elavl4 after chemotherapy mimics improved survival of anti-ELAVL4 antibody-positive small cell lung cancer patients
Introduction: Small cell lung cancer (SCLC) patients have an ~8% 5-year survival; new therapies are urgently needed. Approximately 15% of SCLC patients have naturally-occurring low-titer antibodies against neuronal ELAVL proteins, associated with improved response to therapy and significantly improved survival. We previously determined that the anti-ELAVL4 response is triggered by…
Small cell lung cancer (SCLC) remains a disease with a dismal prognosis, offering only an 8% chance of survival after five years. However, a small percentage of SCLC patients naturally possess antibodies against specific ELAVL proteins, which have been linked to better treatment outcomes and longer survival. In a study, researchers sought to determine if inducing an anti-ELAVL4 response could enhance SCLC survival.
They focused on isoaspartylated Elavl4, a segment of the protein that, when modified, triggers the desired immune response.
Using a mouse model of SCLC, the researchers tested two scenarios. In the first, they immunized mice with isoAsp-Elavl4, a modified version of the protein, before introducing SCLC cells. The intention was to determine if preemptive immunization would improve survival rates. In the second scenario, they waited until after administering three rounds of chemotherapy with cisplatin and etoposide, before administering isoAsp-Elavl4. The aim was to assess if post-chemotherapy immunization could boost survival.
The results indicated that mice pre-immunized with isoAsp-Elavl4 did not exhibit any significant difference in survival rates compared to those not immunized. However, those immunized with isoAsp-Elavl4 following chemotherapy treatment showed a marked improvement in survival. This finding suggests that a post-chemotherapy immune response can be harnessed to enhance the effectiveness of SCLC treatments.
By leveraging the body's natural immune response to isoaspartylated Elavl4, researchers propose a new therapeutic strategy that could potentially improve outcomes for SCLC patients.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
